*Division of Medical Oncology, Department of Oncology
†Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
J.D. and D.M. contributed equally.
D.B. has provided advisory board participation or received honoraria from Amgen Canada, Bristol-Myers-Squibb, AstraZeneca, and Takeda. J.R. has provided advisory board participation or received honoraria from Roche, Novartis, Merck, Lilly, and AstraZeneca. The remaining authors declare no conflicts of interest.
Correspondence: Jacques Raphael, MD, MSc, Department of Oncology, London Health Sciences Centre, 800 Commissioners Road East, Room A3-946, London, ON, N6A 5W9, Canada. E-mail: [email protected]
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com